Livi.Si

LIVI.SI maintains a liquidity position with a current ratio of 1.02, indicating a balanced short-term liquidity profile, though it is not significantly above the threshold of 1.0. The company's cash and equivalents amount to SGD 3,005,190, which is offset by long-term debt of SGD 5,568,330, resulting in a net cash position that is negative. This suggests a potential liquidity risk, as the company's cash reserves are insufficient to cover its long-term obligations.

In terms of profitability, LIVI.SI reports a return on equity (ROE) of 8.68% and a return on assets (ROA) of 2.79%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating income of SGD 70,010 is relatively low compared to the company's revenue of SGD 27,648,430, suggesting that the company is not generating strong operating margins.

The company's revenue is primarily concentrated in its core pharmaceutical services and equipment segment, with no significant geographic diversification reported in the available data. This lack of diversification may expose the company to regional economic fluctuations and regulatory changes that could impact its revenue streams.

Looking at the growth trajectory, LIVI.SI's revenue has shown a decline from the previous period, with the last actual revenue reported at SGD 191,910,000 compared to the current period's revenue of SGD 27,648,430. This represents a significant drop, indicating a potential challenge in maintaining revenue growth. The company's free cash flow of SGD 2,412,360 is positive, but the capital expenditure of SGD -280,450 suggests that the company is not significantly investing in new projects or expansion.

The risk assessment for LIVI.SI indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose a challenge in meeting long-term obligations. However, the dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term.

Recent events and filings do not provide specific details on new initiatives or strategic moves by LIVI.SI. The company's last actual EPS was reported at -SGD 217.50, indicating a loss per share, which may affect investor sentiment and stock performance.